New blood treatment may reduce transfusions during major surgery
NCT ID NCT05711524
First seen Nov 21, 2025 · Last updated May 11, 2026 · Updated 17 times
Summary
This study tested whether a pathogen-reduced blood product (INTERCEPT fibrinogen complex) works as well as standard cryoprecipitate to control bleeding in 208 adults undergoing heart or liver transplant surgery. The goal was to see if having this product readily available could reduce the need for additional blood transfusions. Results will help improve bleeding management during these high-risk surgeries.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLEEDING are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
New York-Presbyterian Hospital/Weill Cornell Medical Center
New York, New York, 10065, United States
Conditions
Explore the condition pages connected to this study.